-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The three major alliances led by Guangdong are finally going to be implemented!
A few days ago, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Procurement Center issued the Notice on Organizing and Carrying out the Confirmation of the Selected and Alternative Varieties of Guangdong Alliance Diclofenac and Other Drugs, Qingkailing and Other Chinese Proprietary Medicines and Alternative Varieties to be Allocated, and Shanxi Province became the first province to issue a notice and take the lead in fully implementing the three batches of Guangdong Alliance centralized procurement
。
On November 18, the Shanxi Provincial Medical Security Bureau issued the Notice on the Implementation of the Centralized Procurement of Guangdong Alliance Diclofenac and Other Drugs, Qingkailing and Other Chinese Proprietary Medicines, and Drugs for Common Diseases and Chronic Diseases, clarifying that all public medical institutions in the province will fully implement the results
of the three batches of Guangdong Alliance centralized procurement drugs from December 20.
The industry view is that Shanxi Province took the lead in announcing that it will fully implement the results of the three batches of centralized procurement drugs of the Guangdong Alliance from December 20, which may drive other provinces to accelerate the implementation
of the alliance procurement.
Up to 98% reduction
It will be fully implemented from December 20
Guangdong Alliance collective procurement is comparable to "small national procurement", which is the largest domestic alliance, the largest variety, the strongest demonstration effect, and the longest implementation of inter-provincial alliance centralized procurement
.
The three projects implemented by the Guangdong Alliance this time are: Guangdong Alliance diclofenac and other drugs, Guangdong Alliance Qingkailing and other proprietary Chinese medicines, and Guangdong Alliance common diseases and chronic diseases
。
The areas of Guangdong Alliance Diclofenac include 11 provinces and regions in Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang and the Xinjiang Production and Construction Corps; The provinces involved in the centralized procurement of proprietary Chinese medicines such as Qingkailing are Guangdong, Shanxi, Henan, Hainan, Ningxia and Qinghai; The alliance areas for the centralized procurement of drugs for common diseases and chronic diseases include Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang, and the Xinjiang Production and Construction Corps
.
Previously, Hainan had issued several pre-notices, and Henan had also made relevant preparations for alternative varieties, but Shanxi was the first province
to announce the full implementation of the three alliances.
According to the Shanxi Provincial Medical Insurance Bureau, there were a total of 494 drugs in the three batches of centralized procurement, and 2,657 products from 616 enterprises were selected, with an average decrease of 32% and a maximum decrease of 98%.
。
Diclofenac and other 276 drugs are collected, the variety range is the national basic medical insurance drug catalogue of large quantities and high purchase amount of chemicals and therapeutic biological products, covering more than 20 types of anti-infective, digestive system, respiratory system, nervous system, cardiovascular system, anti-tumor drugs, blood products, basic infusion and other more than 20 types of drugs;
The collection and procurement of proprietary Chinese medicines involves 132 drugs, covering commonly used proprietary Chinese medicines such as respiratory system, cardiovascular system and nervous system.
The collection of common diseases and chronic diseases involves 86 drugs for common diseases and chronic diseases, mainly antibacterial drugs, hemostatic drugs, painkillers, cardiovascular disease drugs, cough and cold medicines, etc
.
The three batches of centralized procurement drugs basically covered the commonly used drugs in various departments of the hospital, and the prices of related drugs were effectively reduced
.
In principle, the procurement cycle agreed is one year
.
In terms of filling in and determining the purchase quantity, there are two platforms to rely on:
For drugs such as diclofenac and proprietary Chinese medicines such as Qingkailing, the Shanxi Provincial Centralized Procurement Center for Pharmaceuticals and Devices relies on the "Guangdong Province Third-party Drug Electronic Trading Platform" to organize medical institutions to complete the selection of the amount to be allocated and the verification of the agreed procurement amount
.
Alternative products are decided by the medical institution to purchase and use, and the pre-purchase quantity filled in by the corresponding medical institution shall be included in the amount
to be allocated for alternative products that are not selected by the medical institution.
For drugs with common and chronic diseases, the Shanxi Provincial Centralized Procurement Center for Pharmaceuticals and Devices will organize medical institutions to complete the data filling in of the agreed purchase volume by relying on the "New Platform for Pharmaceutical and Equipment Procurement in Shanxi Province
".
It is understood that up to now, Shanxi Province has participated in the Guangdong Alliance drug centralized procurement has carried out four batches, namely, 45 drugs such as amoxicillin, 276 drugs such as diclofenac, 132 proprietary Chinese medicines such as Qingkailing, and 86 common and chronic diseases, with a total of 539 drugs
.
The volume-price linkage is obvious
Do a good job in provincial quantity planning
From the perspective of rules, the rules for the collective procurement of drugs such as Diclofenac in Guangdong Alliance and proprietary Chinese medicines such as Qingkailing are very similar
.
The products are divided into two groups, A and B, group A is the enterprise with a large amount of reporting, and group B is the enterprise
with a small amount of report.
When bidding for bidding, enterprises need to quote two prices P1/P2 at the same time, and exchange the price for the purchase quantity, reflecting the idea
of linking volume and price.
For enterprises whose products participate in both P1 and P2 auctions, but are not selected in the P2 auction, the corresponding products are alternative products, and if the allocation quantity is selected as an alternative product, the corresponding proportion
of the pre-purchase volume in the first year will be obtained.
Some insiders pointed out that the Guangdong Alliance is not strongly restrictive for the alliance provinces other than Guangdong, and the A-proposed alternative products of glucose/sodium chloride/glucose sodium chloride injection, non-exclusive drugs and exclusive drugs are decided by the provinces in the alliance region according to the actual situation
.
This means that a product may face fragmented bidding from multiple different provincial alliances, and enterprises should make selection and reporting plans
according to the rules of different provincial alliances.
However, there is also a view that the alternative variety is the status of a substitute, as long as the selected variety does not make mistakes, the candidate variety has basically lost the opportunity
to obtain procurement volume in the provincial alliance.
For the unselected varieties of centralized procurement, according to the current practice in various provinces, the price of the hanging net should meet the gradient price reduction requirements of the national joint procurement office and not be higher than the lowest price in the national provincial implementation of the hanging net price (that is: the lowest price in the country), this part of the market share is mainly occupied by the original research drug or large brands, and it is also more difficult
for alternative varieties to compete for market share in it.
In general, whether it is national centralized procurement or provincial alliance centralized procurement, it has squeezed the inflated prices of related drugs, which not only reduces the burden of medical expenses on the masses, enhances the sense of gain of the masses, but also reduces the advantages of overseas manufacturers and accelerates the process
of domestic substitution of related drugs.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
